Cardiff Oncology (CRDF) Earnings Analysis
Cardiff Oncology (CRDF) has no confirmed upcoming earnings date. Last quarter (2026-05-14) it missed with EPS -0.18 USD vs -0.13 USD est (-38.5%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -1.28.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CRDF next report earnings?
No confirmed upcoming earnings date is currently scheduled for CRDF. This page updates as the calendar is published.
CRDF earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -0.18 USD | -0.13 USD | -38.5% | Miss |
| 2025-11-06 | -0.17 USD | -0.2 USD | +15% | Beat |
| 2025-05-08 | -0.2 USD | -0.19 USD | -5.3% | Miss |
| 2025-02-27 | -0.21 USD | -0.26 USD | +19.2% | Beat |
| 2024-11-07 | -0.25 USD | -0.27 USD | +7.4% | Beat |
| 2024-08-08 | -0.26 USD | -0.25 USD | -4% | Miss |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
CRDF valuation and analyst view
| Trailing P/E | -1.28 |
|---|---|
| Trailing EPS | -0.65489 USD |
| Price / book | 1.69 |
| Dividend yield | 0.00% |
| Market cap | 0.06B |
| Analyst consensus | Buy (7 buy / 6 hold / 1 sell) |
| Avg price target | 2 USD |
Related research pages
Frequently asked questions
When is Cardiff Oncology (CRDF)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CRDF. This page updates as the calendar is published.
Did CRDF beat earnings last quarter?
In its 2026-05-14 report, CRDF posted EPS of -0.18 USD versus a -0.13 USD estimate — a miss of 38.5%.
What is CRDF's earnings track record?
Over the last 6 reported quarters with consensus data, CRDF beat estimates 3 times (50%).
What is CRDF's current P/E ratio and EPS?
CRDF trades at a trailing P/E of -1.28 on trailing EPS of -0.6548939283101682 USD.
What do analysts rate CRDF?
Analyst consensus is "Buy" across 14 ratings (0 strong buy, 7 buy, 6 hold, 1 sell, 0 strong sell). Average 12-month price target: 2 USD.